Show simple item record

dc.creatorGutiérrez, José María
dc.creatorLeón Montero, Guillermo
dc.creatorLomonte, Bruno
dc.creatorAngulo Ugalde, Yamileth
dc.date.accessioned2017-02-27T17:17:04Z
dc.date.available2017-02-27T17:17:04Z
dc.date.issued2011-10
dc.identifier.citationhttp://www.eurekaselect.com/88786/articlees_ES
dc.identifier.issn2212-4055
dc.identifier.urihttp://hdl.handle.net/10669/29558
dc.descriptionVersión final embargada hasta 2081-10 por política editoriales_ES
dc.description.abstractAnimal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. Antivenoms are manufactured by immunizing animals, usually horses, with venoms from a single or several medically-relevant snake species. Antivenoms are constituted by either whole IgG molecules or the immunoglobulin fragments F(ab)2 and Fab, obtained by digestion with pepsin and papain, respectively. Differences in the pharmacokinetics of these active substances have pharmacodynamic implications. Novel technological possibilities may improve the quality of antivenoms in the future, as well as their microbial safety. Antivenom administration might induce early and late adverse reactions, whose possible mechanisms are discussed. Owing to the large variety in the composition of snake venoms and to the need to demonstrate neutralization of relevant snake venoms in different countries, a meticulous preclinical and clinical assessment of antivenom efficacy and safety is required before an antivenom is introduced into clinical application. The accessibility of antivenoms in low-income tropical countries is of concern and efforts should be directed at guaranteeing the access of safe and effective antivenoms at affordable prices and their correct clinical use in these countries.es_ES
dc.description.sponsorshipUniversidad de Costa Rica//UCR/Costa Ricaes_ES
dc.description.sponsorshipPrograma Iberoamericano de Ciencia y Tecnología para el Desarrollo/[206AC0281]/CYTED/Españaes_ES
dc.language.isoen_USes_ES
dc.sourceInflammation & Allergy - Drug Targets; Volumen 10, Número 5. 2011es_ES
dc.subjectSnakebitees_ES
dc.subjectNeglected tropical diseaseses_ES
dc.subjectAntivenomses_ES
dc.subjectEnvenominges_ES
dc.subjectFractionationes_ES
dc.subjectQuality controles_ES
dc.subjectPharmacokinetices_ES
dc.subjectViral safetyes_ES
dc.subjectAdverse reactionses_ES
dc.subjectAntivenom Efficacyes_ES
dc.subjectHyperimmune Plasmaes_ES
dc.subjectSnake venomes_ES
dc.titleAntivenoms for Snakebite Envenomingses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.typeArtículo científicoes_ES
dc.identifier.doi10.2174/187152811797200669
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.identifier.pmid21745181


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record